Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 839,461 shares of the medical equipment provider’s stock after selling 28,859 shares during the period. Thrivent Financial for Lutherans’ holdings in Zimmer Biomet were worth $88,672,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Mystic Asset Management Inc. acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $287,000. Tocqueville Asset Management L.P. acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $560,000. Cibc World Markets Corp grew its stake in shares of Zimmer Biomet by 13.9% during the fourth quarter. Cibc World Markets Corp now owns 31,614 shares of the medical equipment provider’s stock worth $3,339,000 after purchasing an additional 3,854 shares in the last quarter. one8zero8 LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $370,000. Finally, Natixis Advisors LLC grew its stake in shares of Zimmer Biomet by 12.1% during the fourth quarter. Natixis Advisors LLC now owns 71,382 shares of the medical equipment provider’s stock worth $7,540,000 after purchasing an additional 7,731 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $112.78 on Wednesday. The stock has a market capitalization of $22.45 billion, a price-to-earnings ratio of 25.34, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90. The company has a 50-day simple moving average of $106.18 and a 200-day simple moving average of $106.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 earnings per share. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.85%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.95% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ZBH shares. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Truist Financial reissued a “hold” rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Raymond James reduced their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.